FDA delays approval of Biogen Idec’s MS drug Plegridy
Posted: Wed Mar 19, 2014 7:00 am
The US Food and Drug Administration has extended the initial Prescription Drug User Fee Act (PDUFA) date for its review of US biotech firm Biogen Idec’s Biologics License Application for Plegridy (peginterferon beta-1a), a subcutaneous pegylated interferon candidate for relapsing forms of multiple sclerosis (RMS)..... Read More - http://www.ms-uk.org/PEGylatedinterferonbeta